Milestone Pharmaceuticals ( ($MIST) ) has issued an announcement. On January 6, 2026, Milestone Pharmaceuticals announced that the European ...

Detailed price information for Milestone Pharmaceuticals Inc (MIST-Q) from The Globe and Mail including charting and trades.

The MAGiC catheter is designed to perform minimally invasive cardiac ablation procedures that treat various forms of ...

Stereotaxis’ CEO said the company has been “hampered clinically, commercially and strategically” by its prior dependence on a J&J catheter.

Stereotaxis has won FDA approval for the MAGiC Magnetic Interventional Ablation Catheter. The device is a robotically ...

SVT results in the heart beating at much faster rate than normal, and can be triggered by exercise, lack of sleep, ...

Stereotaxis plans to launch the MAGiC cardiac ablation catheter in early 2026, CEO and Chair David Fischel tells MassDevice.

Stereotaxis CEO David Fischel says the MAGiC catheter was designed "to overcome the natural limitations of manual pull-wire ...

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, ...

The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), maker Milestone Pharmaceuticals announced. The rapid-acting L-type calcium ...

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S.

Investing.com -- Stereotaxis (NYSE:STXS) stock surged 8.3% Tuesday after the surgical robotics company announced it received U.S. Food and Drug Administration (FDA) approval for its MAGiC Magnetic ...